Yaw Senyah

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

John H. Kehne, B M Baron, A A Carr et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 359 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

Mark D. Black, Rachel J. Stevens, Nancy Rogacki et al. · Psychopharmacology · 2010 · 54 citations

Medicine, Pharmacology, Psychiatry +15

Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist

Bruce M. Baron, Boyd L. Harrison, John H. Kehne et al. · European Journal of Pharmacology · 1997 · 48 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs

Mark D. Black, Jeff Simmonds, Yaw Senyah et al. · Neuropharmacology · 2002 · 33 citations

Medicine, Neurobiology, Neuroscience +13

MDL 27,531 selectively reverses strychnine‐induced seizures in mice

John H. Kehne, John M. Kane, Francis P. Miller et al. · British Journal of Pharmacology · 1992 · 21 citations · Full text

Medicine, Neuroscience, Pharmacology +15